百日咳诊断:现行标准的局限性和GPI建议

doi:10.7499/j.issn.1008-8830.2016.09.020

PDF(1630 KB)

HTML

中国当代儿科杂志 ›› 2016, Vol. 18 ›› Issue (9) : 891-896. DOI: 10.7499/j.issn.1008-8830.2016.09.020

专家讲座

百日咳诊断:现行标准的局限性和GPI建议

姚开虎¹, 邓继岿², 热夏提·达吾提³

作者信息 +

Pertussis diagnosis: the limitation of the currently used criteria and the suggestion of Global Pertussis Initiative

YAO Kai-Hu¹, DENG Ji-Kui², REXIATI Dawuti³

Author information +

文章历史 +

摘要

现已认识到百日咳是一个影响全年龄段人群的疾病，现行不分年龄段的“一刀切”式的诊断标准存在明显局限性，不利于及时地开始个体治疗和阻断传播的工作。全球百日咳计划（Global Pertussis Initiative,GPI）专家组于是拟定了新的百日咳诊断标准建议。该讲座结合相关研究，综合分析了现行标准的不足，并详细介绍了GPI提出的百日咳诊断建议。

Abstract

It has been recognized that pertussis is a disease that affects all age groups. There are obvious limitations in the currently used diagnostic criteria with "one-size-fits-all" definition, which is not advantageous to start individual treatment and perform strategies for preventing the transmission. Therefore, the expert group of Global Pertussis Initiative gives a suggestion for the diagnosis of pertussis. Based on the related published studies, the present article analyzes the limitations of the current criteria, and introduces the GPI's suggestion in detail.

导出引用

姚开虎, 邓继岿, 热夏提·达吾提. 百日咳诊断:现行标准的局限性和GPI建议[J]. 中国当代儿科杂志. 2016, 18(9): 891-896 https://doi.org/10.7499/j.issn.1008-8830.2016.09.020

YAO Kai-Hu, DENG Ji-Kui, REXIATI Dawuti. Pertussis diagnosis: the limitation of the currently used criteria and the suggestion of Global Pertussis Initiative[J]. Chinese Journal of Contemporary Pediatrics. 2016, 18(9): 891-896 https://doi.org/10.7499/j.issn.1008-8830.2016.09.020

参考文献

[1] Cherry JD, Tan T, Wirsing von König CH, et al. Clinical definitions of pertussis:Summary of a Global Pertussis Initiative roundtable meeting, February 2011[J]. Clin Infect Dis, 2012, 54(12):1756-1764.
[2] Forsyth KD, Wirsing von Konig CH, Tan T, et al. Prevention of pertussis:recommendations derived from the second Global Pertussis Initiative roundtable meeting[J]. Vaccine, 2007, 25(14):2634-2642.
[3] World Health Organization; Dept. of Vaccines and Biologicals. WHO-recommended standards for surveillance of selected vaccine-preventable diseases[EB/OL]. (February 2003). http://apps.who.int/iris/bitstream/10665/68334/1/WHO_V-B_03.01_eng.pdf.
[4] Centers for Disease Control and Prevention (CDC). Manual for the Surveillance of Vaccine-Preventable Diseases:Chapter 10:Pertussis[EB/OL]. (January 1, 2014). http://www.cdc.gov/vaccines/pubs/surv-manual/chpt10-pertussis.html#laboratory.
[5] Department of Health, Australian Government. Pertussis case definition[EB/OL]. (January 16, 2014). http://www.health.gov.au/internet/main/publishing.nsf/Content/cda-surveil-nndsscasedefs-cd_pertus.htm.
[6] 中华人民共和国卫生部. 百日咳诊断标准及处理原则[EB/OL]. (1995-12-15). http://www.moh.gov.cn/zwgkzt/s9491/201212/34026.shtml.
[7] 中华人民共和国卫生部. WS 274-2007百日咳诊断标准[EB/OL]. (2007-04-17). http://www.moh.gov.cn/zwgkzt/s9491/201410/52040bc16d3b4eecae56ec28b3358666.shtml.
[8] Nieves DJ, Heininger U. Bordetella pertussis[J]. Microbiol Spectr, 2016, 4(3). doi:10.1128/microbiolspec.EI10-0008-2015.
[9] Cherry JD. Epidemic pertussis in 2012-the resurgence of a vaccine-preventable disease[J]. N Engl J Med, 2012, 367(9):785-787.
[10] Cherry JD, Grimprel E, Guiso N, et al. Defining pertussis epidemiology:clinical, microbiologic and serologic perspectives[J]. Pediatr Infect Dis J, 2005, 24(5 Suppl):S25-S34.
[11] Koh MT, Liu CS, Chiu CH, et al. Under-recognized pertussis in adults from Asian countries:a cross-sectional seroprevalence study in Malaysia, Taiwan and Thailand[J]. Epidemiol Infect, 2016, 144(6):1192-1200.
[12] He H, Yao P, Zhou Y, et al. Is pertussis infection neglected in China? Evidence from a seroepidemiology survey in Zhejiang,an eastern province of China[J]. PLoS One, 2016, 11(5):e0155965.
[13] Chen Z, Zhang J, Cao L, et al. Seroprevalence of pertussis among adults in China where whole cell vaccines have been used for 50 years[J]. J Infect, 2016, 73(1):38-44.
[14] Mattoo S, Cherry JD. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies[J]. Clin Microbiol Rev, 2005, 18(2):326-382.
[15] Schmitt-Grohé S, Cherry JD, Heininger U, et al. Pertussis in German adults[J]. Clin Infect Dis, 1995, 21(4):860-866.
[16] Huygen K, Rodeghiero C, Govaerts D, et al. Bordetella pertussis seroprevalence in Belgian adults aged 20-39 years, 2012[J]. Epidemiol Infect, 2014, 142(4):724-728.
[17] Guiso N, Berbers G, Fry NK, et al. What to do and what not to do in serological diagnosis of pertussis:recommendations from EU reference laboratories[J]. Eur J Clin Microbiol Infect Dis, 2011, 30(3):307-312.
[18] Ghanaie RM, Karimi A, Sadeghi H, et al. Sensitivity and specificity of the World Health Organization pertussis clinical case definition[J]. Int J Infect Dis, 2010, 14(12):e1072-e1075.
[19] Strebel P, Nordin J, Edwards K, et al. Population-based incidence of pertussis among adolescents and adults, Minnesota, 1995-1996[J]. J Infect Dis, 2001, 183(9):1353-1359.
[20] Miyashita N, Akaike H, Teranishi H, et al. Diagnostic value of symptoms and laboratory data for pertussis in adolescent and adult patients[J]. BMC Infect Dis, 2013, 13:129.
[21] Nieves DJ, Singh J, Ashouri N, et al. Clinical and laboratory features of pertussis in infants at the onset of a California epidemic[J]. J Pediatr, 2011, 159(6):1044-1046.
[22] Shojaei J, Saffar M, Hashemi A, et al. Clinical and laboratory features of pertussis in hospitalized infants with confirmed versus probable pertussis cases[J]. Ann Med Health Sci Res, 2014, 4(6):910-914.
[23] Patriarca PA, Biellik RJ, Sanden G, et al. Sensitivity and specificity of clinical case definitions for pertussis[J]. Am J Public Health, 1988, 78(7):833-836.
[24] Stehr K, Cherry JD, Heininger U, et al. A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine[J]. Pediatrics, 1998, 101(1 Pt 1):1-11.